<DOC>
	<DOC>NCT02709187</DOC>
	<brief_summary>An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R208 (Candesartan cilexetil 8mg/Rosuvastatin 10mg), a fixed dose combination compared with coadministration of separate constituents in healthy adult volunteers</brief_summary>
	<brief_title>DP-R208 Pharmacokinetic Study</brief_title>
	<detailed_description />
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>BMI 18~30 signed the informed consent form prior to the study participation Clinically significant disease Previously donate whole blood within 60 days or component blood within 14 days Clinically significant allergic disease Taken IP in other trial within 90 days An impossible one who participates in clinical trial by investigator's decision including laboratory test result</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>DP-R208</keyword>
</DOC>